{
  "id": 2163919,
  "title": "Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds",
  "url": "https://urgent.news/2026/08/20/using-gray-market-versions-of-lillys-triple-g-leads-to-relatively",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-20T15:12:43.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/using-gray-market-versions-of-lillys-triple-g-leads-to-relatively-poor-weight-loss-study-finds/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of up to 25% in Phase 3. This has led growing ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}